Amit Jethanandani
Overview
Amit Jethanandani, MD, MPH, is an assistant professor in the Department of Radiation Oncology at Emory University School of Medicine. A radiation oncologist, Dr. Jethanandani specializes in the treatment of head and neck cancer. He is an attending physician at Winship Cancer Institute at Emory Midtown.
Dr. Jethanandani completed both his preliminary year and earned his MD at the University of Tennessee Health Science Center. He received his Master of Public Health from The University of Texas Health Science Center, School of Public Health. He completed his residency in radiation oncology at the University of Miami.
Dr. Jethanandani's research focuses primarily on head and neck cancer, including important work on machine learning and adaptive radiotherapy administration. He is the recipient of both an Alpha Omega Alpha grant and an RSNA grant.
Academic Appointment
- Assistant Professor, Department of Radiation Oncology, Emory University School of Medicine
Education
Degrees
- MD from University of Tennessee Health Science Center
- MPH from The University of Texas Health Science Center at Houston
Research
Publications
-
18FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer.
Clin Transl Radiat Oncol Volume: 29 Page(s): 93 - 101
07/01/2021 Authors: Elhalawani H; Cardenas CE; Volpe S; Barua S; Stieb S; Rock CB; Lin T; Yang P; Wu H; Zaveri J -
Detecting the Dark Matter of Unpublished Clinical Cancer Studies: An Analysis of Phase 3 Randomized Controlled Trials.
Mayo Clin Proc Volume: 96 Page(s): 420 - 426
02/01/2021 Authors: Pasalic D; Fuller CD; Mainwaring W; Lin TA; Miller AB; Jethanandani A; Espinoza AF; Grossberg AJ; Jagsi R; Das P -
Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy.
Br J Cancer Volume: 124 Page(s): 628 - 633
02/01/2021 Authors: Ng SP; Bahig H; Jethanandani A; Sturgis EM; Johnson FM; Elgohari B; Gunn GB; Ferrarotto R; Phan J; Rosenthal DI -
Professional Medical Writer Assistance in Oncology Clinical Trials.
Oncologist Volume: 25 Page(s): e1812 - e1815
11/01/2020 Authors: Kouzy R; Abi Jaoude J; Mainwaring W; Lin TA; Miller AB; Jethanandani A; Espinoza AF; Verma V; Fuller CD; Minsky BD -
Racial and Ethnic Disparities Among Participants in US-Based Phase 3 Randomized Cancer Clinical Trials.
JNCI Cancer Spectr Volume: 4 Page(s): pkaa060
10/01/2020 Authors: Grant SR; Lin TA; Miller AB; Mainwaring W; Espinoza AF; Jethanandani A; Walker GV; Smith BD; Ashleigh Guadagnolo B; Jagsi R -
Performance Status Restriction in Phase III Cancer Clinical Trials.
J Natl Compr Canc Netw Volume: 18 Page(s): 1322 - 1326
10/01/2020 Authors: Abi Jaoude J; Kouzy R; Mainwaring W; Lin TA; Miller AB; Jethanandani A; Espinoza AF; Pasalic D; Verma V; VanderWalde NA -
Trial Sponsorship and Time to Reporting for Phase 3 Randomized Cancer Clinical Trials.
Cancers (Basel) Volume: 12
09/16/2020 Authors: Lin TA; Fuller CD; Verma V; Mainwaring W; Espinoza AF; Miller AB; Jethanandani A; Pasalic D; Das P; Minsky BD -
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials.
Eur J Cancer Volume: 136 Page(s): 176 - 185
09/01/2020 Authors: Pasalic D; McGinnis GJ; Fuller CD; Grossberg AJ; Verma V; Mainwaring W; Miller AB; Lin TA; Jethanandani A; Espinoza AF -
Exclusion of Men from Randomized Phase III Breast Cancer Clinical Trials.
Oncologist Volume: 25 Page(s): e990 - e992
06/01/2020 Authors: Corrigan KL; Mainwaring W; Miller AB; Lin TA; Jethanandani A; Espinoza AF; Piotrowski M; Fuller CD; Stauder MC; Shaitelman SF -
Non-English language validation of patient-reported outcome measures in cancer clinical trials.
Support Care Cancer Volume: 28 Page(s): 2503 - 2505
06/01/2020 Authors: Grant SR; Noticewala SS; Mainwaring W; Lin TA; Miller AB; Jethanandani A; Espinoza AF; Gunn GB; Fuller CD; Thomas CR